Article Text
Aetiology/Harm
Cohort Study
Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder
Statistics from Altmetric.com
Footnotes
Competing interests RE Nielsen has received research grants from H Lundbeck for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals and Eli Lilly and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda and Medivir.
RW Licht has received grant from GlaxoSmithKline for clinical trial, received speaker fees from Eli Lilly, Janssen-Cilag, Bristol-Myers Squibb, Pfizer, Astra-Zeneca, Lundbeck, GlaxoSmithKline, Otsuka, Servier and has acted as advisor for Bristol-Myers Squibb, Astra Zeneca, Janssen-Cilag, Otsuka, Eli Lilly and MSD.
Provenance and peer review Commissioned; internally peer reviewed.